Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET

Inclusion Criteria

• •Histologically confirmed Hodgkin´s Lymphoma (WHO Classification 1999)
• •1. Classical Hodgkin Lymphoma: Nodular sclerosis (type 1 and 2) / Mixed type / Lymphocyte depleted type / Lymphocyte rich type
• •2. Nodular lymphocyte-predominant Hodgkin Lymphoma
• •Patients in stage: Clinical stage (CS) I without risk factors / CS II without risk factors
• •Age between 16 and 75
• •Written informed consent
• •Histologically confirmed Hodgkin´s Lymphoma (WHO Classification 1999)
• •1. Classical Hodgkin´s Lymphoma: Nodular sclerosis (type 1 and 2) / Mixed type / Lymphocyte depleted type / Lymphocyte rich type
• •2. Nodular lymphocyte-predominant Hodgkin Lymphoma
• •Patients in stage
• •1. Clinical stage (CS) I,II A with risk factors: Large mediastinal tumor (\>1/3 of the maximal diameter of the thoracic cavity) / Extranodal disease / Sedimentation rate ≥ 50 mm/h for patients without B-symptomes or ≥ 30 mm/h for patients with B-symptomes / ≥ 3 lymph node areas infiltrated with tumor cells
• •2. Clinical stage (CS) II B with risk factors: Sedimentation rate ≥ 50 mm/h for patients without B-symptomes or ≥ 30 mm/h for patients with B-symptomes / ≥ 3 lymph node areas infiltrated with tumor cells
• •Age between 16 and 75
• •Written informed consent
• •Histologically confirmed Hodgkin´s Lymphoma (WHO Classification 1999)
• •1. Classical Hodgkin's Lymphoma (Hodgkin's desease): Nodular sclerosis (type 1 and 2) / Mixed type / Lymphocyte depleted type / Lymphocyte rich type
• •2. Nodular lymphocyte-predominant Hodgkin Lymphoma
• •Patients in stage
• •1. Clinical stage (CS) II B with minimum one of the following risk factors: Large mediastinal tumor (≥1/3 of the maximal diameter of the thoracic cavity) / Extranodal disease
• •2. Clinical stage (CS) III
• •3. Clinical stage (CS) IV
• •Age between 16 and 65
• •Written informed consent